BiotechTubeBiotechTube
Home/Pipeline/Lead CAR-T Program

Lead CAR-T Program

Hematologic Malignancies

Phase 1Active

Key Facts

Indication
Hematologic Malignancies
Phase
Phase 1
Status
Active
Company
Arcellx

About Arcellx

Arcellx is pioneering next-generation cell therapies for cancer patients, leveraging proprietary technologies to develop more effective and durable CAR-T cell treatments. The company's lead programs target hematologic malignancies with novel approaches designed to improve patient outcomes and overcome treatment resistance. As a publicly traded company, Arcellx is advancing multiple clinical programs while building a robust pipeline of innovative cellular immunotherapies.

View full company profile

Therapeutic Areas

OncologyHematologyImmunotherapy

Other Hematologic Malignancies Drugs

DrugCompanyPhase
SHR-1905Jiangsu Hengrui MedicinePhase 1
Rituximab biosimilar (IBI301)Innovent BiologicsApproved
Alemtuzumab BiosimilarCSPC Pharmaceutical Group LimitedPhase 3
KT-333Kymera TherapeuticsPhase 1
Undisclosed CAR-T programsBeam TherapeuticsDiscovery/Preclinical
NX-1607Nurix TherapeuticsPhase 1a
Trichostatin A (TSA)Vanda PharmaceuticalsOncology Program
Cord Blood HSC UnitGlobal Cord BloodApproved/Commercial
TSC-102-A01TScan TherapeuticsPreclinical
TSC-102-A03TScan TherapeuticsPreclinical
LBL-007LakeShore BiopharmaPhase 1
CER-T Cell PlatformCERo TherapeuticsPre-clinical